Syndax Pharmaceuticals, Inc. (SNDX) Presents at The 67th American Society of Hematology (ASH) Annual Meeting Transcript

Core Insights - The company is presenting at the ASH conference, highlighting advancements in clinical trials and patient care [1] Group 1: Clinical Trials and Research - Dr. DeFilipp from MGH will discuss the latest data on chronic GVHD, showcasing the company's commitment to advancing treatment options [2] - Dr. Sallman from Moffitt Cancer Center will present real-world evidence for a menin inhibitor, marking a significant development in the treatment paradigm for acute leukemia [2] - Dr. Jabbour will provide insights on post-transplant maintenance data and results from the frontline AML trial, further emphasizing the company's research efforts [2]